Head to Head Analysis: Scpharmaceuticals (NASDAQ:SCPH) vs. Bayer (NASDAQ:BAYRY)

Scpharmaceuticals (NASDAQ:SCPH) and Bayer (OTCMKTS:BAYRY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares Scpharmaceuticals and Bayer’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Scpharmaceuticals N/A N/A -$29.44 million ($1.59) -3.81
Bayer $46.75 billion 1.41 $2.00 billion $1.75 10.11



Bayer has higher revenue and earnings than Scpharmaceuticals. Scpharmaceuticals is trading at a lower price-to-earnings ratio than Bayer, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Scpharmaceuticals and Bayer, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scpharmaceuticals 0 2 0 0 2.00
Bayer 1 5 1 0 2.00

Scpharmaceuticals presently has a consensus target price of $5.00, suggesting a potential downside of 17.36%. Given Scpharmaceuticals’ higher probable upside, analysts plainly believe Scpharmaceuticals is more favorable than Bayer.

Dividends

Bayer pays an annual dividend of $0.55 per share and has a dividend yield of 3.1%. Scpharmaceuticals does not pay a dividend. Bayer pays out 31.4% of its earnings in the form of a dividend.

Profitability

This table compares Scpharmaceuticals and Bayer’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Scpharmaceuticals N/A -36.26% -29.52%
Bayer 2.43% 12.69% 4.66%

Volatility & Risk

Scpharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Bayer has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Insider and Institutional Ownership

40.2% of Scpharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Bayer shares are held by institutional investors. 4.1% of Scpharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Bayer beats Scpharmaceuticals on 10 of the 14 factors compared between the two stocks.

About Scpharmaceuticals

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, cosmetics, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, cold and cough, foot care, and sun protection categories. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The Animal Health segment develops and markets products and solutions for the prevention and treatment of disease in companion and farm animals to veterinarians. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.